19hon MSN
PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
Get key insights from PDS Biotech’s Q3 2025 earnings call, including regulatory updates for PDS0101 in HPV16+ cancer and financial highlights.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback